Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Nissan Plans Major Lineup Cuts and AI Expansion in Bid for Global Sales Recovery 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
HEIDELBERG, Germany, Oct. 31, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7, 2016 at 10:30 a.m. (MT) in Scottsdale, AZ.
A live webcast of the conference presentation can be accessed through the “Events” section on the “Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact: Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: [email protected] or [email protected] Media Contact: Anca Alexandru, Head of Communications, EU IR Phone: +49 6221 64793341 E-Mail: [email protected]
